<DOC>
	<DOCNO>NCT00751803</DOCNO>
	<brief_summary>The objective trial ass safety , tolerability , efficacy three dos BI 44370 TA treatment patient acute migraine attack headache pain moderate severe intensity , compare placebo active comparator .</brief_summary>
	<brief_title>BI 44370 TA Acute Migraine Attack</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Eletriptan</mesh_term>
	<criteria>Adult migraine patient without aura , diagnose accord ICH . Established migraine diagnosis great equal 1 year . Age first migraine onset late 50 year age . Medical history migraine headache moderate severe intensity migraine frequency 28 times/ month . Patient provide write informed consent accordance ICHGCP local legislation . History hemiplegic , ophthalmoplegic basilar migraine , cluster headache . History treatmentresistant migraine attack . Other pain syndrome possibly interfere study assessment use pain medication &gt; 10 day / month . Use migraine restrict medication , restriction per protocol . Pregnancy breastfeed . Female childbearing potential use contraception . Clinically significant cardiovascular , peripheral vascular , hepatic , respiratory , haematological , gastrointestinal , renal , metabolic , immunological , hormonal , neurological psychiatric disorder . Patients unrecognised coronary artery disease likely , risk coronary artery disease indicate presence risk factor . Persistent liver enzyme elevation ALT , AST AP &gt; 2x ULN . Known history HIV , history cancer within last 5 year . DSMIVdefinedhistory substance abuse dependence within past 6 month , exclude nicotine caffeine , include alcohol benzodiazepine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>